(Corrects spelling of Repatha, paragraph 1)
By Jan Wolfe
Feb 25 (Reuters) - A U.S. jury said on Monday that patents owned by Amgen Inc on its cholesterol drug Repatha are valid, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA, Bloomberg reported.
Sanofi and Regeneron had stipulated that if the Amgen patents were valid, their jointly developed cholesterol drug Praluent infringed them.
Thousand Oaks, California-based Amgen won a similar verdict in 2016, as well as a court order blocking Praluent sales, but an appeals court set aside the victory and ordered a new trial.
Reporting by Jan Wolfe; Editing by Cynthia Osterman and Richard Chang